Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of INS018_055 in Healthy Subjects
NCT05154240Phase 1Completed
- Sponsor
- Insilico Medicine
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing INS018_055 with Placebo (2 arms). Primary endpoint: Number of participants with treatment-related adverse events at 12 months. Started Feb 2022; status: completed.
02
Drugs
INS018_055
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05154240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154240.